MediNewsDigest: Good news indeed for some patients on Glivec (Imanitib)  for CML ( Chronic Myeloid Leukemia), but at this time a small minority

The criteria for treatment cessation according to the study is “deep molecular remission”.  A treatment response is called a complete molecular remission if no leukemia cells  in the blood and/or marrow can be detected by PC. (Leukemia and lymphoma society)

PCR:   Polymerase Chain Reaction (PCR, a method of amplifying specific regions of DNA) to study seven long-term survivors of chronic myeloid leukemia . . .(Journal Watch)

Quoting:

“…Therefore, patients treated with imatinib who are candidates for treatment interruption are rare … (and) might represent 10 percent of patients..”   (Reuters)

Leave a Reply

Your email address will not be published. Required fields are marked *

Current month ye@r day *

© 2013-2019 Medical News Digest All Rights Reserved